OraSure Technologies, Inc. (OSUR) stock analysis
Healthcare · Medical Instruments & Supplies
From the 10-K filed 2026-03-09
Business type: Asset play
How it makes money
It generates revenue by selling diagnostic tests and sample collection devices to clinical, research, and government organizations, with diagnostic volume being the primary driver.
The company produces medical diagnostics for infectious diseases and physical collection tools for biological samples. Revenue depends heavily on the adoption of these products by healthcare systems and research facilities, as well as OTC market success for select test kits.
What protects it: the moat
It relies on regulatory clearances and proprietary technology to defend its market position, though management acknowledges intense competition in the diagnostics space.
The company seeks to secure market space through FDA approvals and specific testing patents. It admits that competitors may develop superior offerings, necessitating constant innovation.
What could damage it
A failure to secure FDA approvals for its product pipeline would halt its revenue growth and invalidate the justification for its heavy R&D spending.
The business model depends on a steady cadence of regulatory clearances. If the FDA denies or delays authorization for new tests, the company cannot commercialize its intellectual property, leading to a permanent loss of expected market share and revenue.
About OraSure Technologies, Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.